Floatz logo

Alpelisib

Advanced Solid Tumors With an Alteration of the PIK3CA Gene

Novartis PharmaceuticalsSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Advanced Solid Tumors With an Alteration of the PIK3CA Gene cohort.

Asset / SponsorPhaseRating
FULVESTRANT
Novartis Pharmaceuticals
Phase 1CC

Same molecule, other indications

Alpelisib is also rated in:

triple-negative breast carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
HER2 positive breast carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
Sickle Cell AnemiaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →